Retraction to: Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia: EFFECT OF BLONANSERIN ON COGNITION IN SCHIZOPHRENIA (Human Psychopharmacology: Clinical and Experimental, (2012), 27, 1, (90-100), 10.1002/hup.1276);Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia

Human Psychopharmacology

Volumn 27, Issue 1, 2012, Pages 90-100

  Tenjin, Tomomi ^a   Miyamoto, Seiya ^a   Miyake, Nobumi ^a   Ogino, Shin ^a   Kitajima, Rei ^a   Ojima, Kazuaki ^a   Arai, Jun ^a   Teramoto, Haruki ^a   Tsukahara, Sachiko ^a   Ito, Yukie ^a   Tadokoro, Masanori ^a   Anai, Kiriko ^a   Funamoto, Yasuyuki ^b   Kaneda, Yasuhiro ^c   Sumiyoshi, Tomiki ^d   Yamaguchi, Noboru ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Psychiatry   (Japan)

^c Department of Psychiatry   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

Author keywords

blonanserin; cognition; letter fluency; quality of life; schizophrenia

Indexed keywords

BLONANSERIN;

ADULT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MALE; MUSCLE TWITCH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; XEROSTOMIA;

EID: 84856347531     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2622     Document Type: Erratum

References (75)

1. Allen HA, Liddle PF, Frith CD,. 1993. Negative features, retrieval processes and verbal fluency in schizophrenia. Br J Psychiatry 163: 769-775. (Pubitemid 23352970)
2. American Psychiatric Association. 2000. Diagnostic Criteria from DSM-IV-TR. American Psychiatric Association: Washington, DC.
3. Andersen R, Fagerlund B, Rasmussen H, et al,. 2011. Cognitive effects of six months of treatment with quetiapine in antipsychotic-naive first-episode schizophrenia. Psychiatry Res 187: 49-54.
4. Baker SC, Rogers RD, Owen AM, et al,. 1996. Neural systems engaged by planning: a PET study of the Tower of London task. Neuropsychologia 34: 515-526. (Pubitemid 26154489)
5. Bilder RM, Goldman RS, Robinson D, et al,. 2000. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 157: 549-559. (Pubitemid 30191193)
6. Birchwood M, Todd P, Jackson C,. 1998. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 172: 53-59. (Pubitemid 28258899)
7. Bokat CE, Goldberg TE,. 2003. Letter and category fluency in schizophrenic patients: a meta-analysis. Schizophr Res 64: 73-78. (Pubitemid 37153351)
8. Bozikas VP, Andreou C,. 2011. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry 45: 93-108.
9. Carpenter WT, Gold JM,. 2002. Another view of therapy for cognition in schizophrenia. Biol Psychiatry 51: 969-971. (Pubitemid 34607713)
10. Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, et al,. 2009. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry 70: 717-729.
11. Dagher A, Owen AM, Boecker H, et al,. 1999. Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain 122 (Pt 10): 1973-1987. (Pubitemid 29473868)
12. Davidson M, Galderisi S, Weiser M, et al,. 2009. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166: 675-682.
13. Deeks ED, Keating GM,. 2010. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs 24: 65-84.
14. Fagerlund B, Mackeprang T, Gade A, et al,. 2004. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 9: 364-374. (Pubitemid 38649725)
15. Gold JM, Harvey PD,. 1993. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 16: 295-312. (Pubitemid 23174755)
16. Goldberg TE, Goldman RS, Burdick KE, et al,. 2007. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64: 1115-1122. (Pubitemid 47529336)
17. Goldberg TE, Keefe RS, Goldman RS, et al,. 2010. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 35: 1053-1062.
18. Gourovitch ML, Kirkby BS, Goldberg TE, et al,. 2000. A comparison of rCBF patterns during letter and semantic fluency. Neuropsychology 14: 353-360.
19. Green MF,. 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321-330. (Pubitemid 26074706)
20. Green MF, Kern RS, Braff DL, et al,. 2000. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26: 119-136. (Pubitemid 30317696)
21. Guy W,. 1976. Clinical Global Impression. US Department of Health and Human Services Publication (ADM): Rockville, MD.
22. Hagger C, Buckley P, Kenny JT, et al,. 1993. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702-712. (Pubitemid 23354783)
23. Harvey PD, Keefe RS,. 2001. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158: 176-184. (Pubitemid 32116511)
24. Hill SK, Bishop JR, Palumbo D, et al,. 2010. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 10: 43-57.
25. Hill SK, Reilly JL, Harris MS, et al,. 2009. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr Res 113: 167-175.
26. Howanitz E, Cicalese C, Harvey PD,. 2000. Verbal fluency and psychiatric symptoms in geriatric schizophrenia. Schizophr Res 42: 167-169. (Pubitemid 30216528)
27. Inada T,. 1996. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage., Yagi G, (ed.). Seiwa shoten: Tokyo.
28. Kaneda Y, Imakura A, Fujii A, et al,. 2002. Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Res 113: 107-113. (Pubitemid 35447728)
29. Kaneda Y, Sumiyoshi T, Keefe R, et al,. 2007. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci 61: 602-609. (Pubitemid 350233482)
30. Kaneda Y, Sumiyoshi T, Nakagome K, et al,. 2008. The brief assessment of cognition in schizophrenia Japanese version (BACS-J). Seishin Igaku (Clinical Psychiatry) 50: 913-917.
31. Kay SR, Fiszbein A, Opler LA,. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276. (Pubitemid 18039085)
32. Keefe RS, Bilder RM, Davis SM, et al,. 2007a. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64: 633-647. (Pubitemid 46878665)
33. Keefe RS, Malhotra AK, Meltzer HY, et al,. 2008. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33: 1217-1228. (Pubitemid 351521707)
34. Keefe RS, Seidman LJ, Christensen BK, et al,. 2004. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161: 985-995. (Pubitemid 38735984)
35. Keefe RSE, Silva SG, Perkins DO, et al,. 1999. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25: 201-222. (Pubitemid 29272501)
36. Keefe RS, Sweeney JA, Gu H, et al,. 2007b. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1061-1071. (Pubitemid 47121395)
37. Kinoshita T,. 2008. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Japan-wide study). Jpn J Clin Psychopharmacol 11: 135-153.
38. Kubota Y, Toichi M, Shimizu M, et al,. 2005. Prefrontal activation during verbal fluency tests in schizophrenia-a near-infrared spectroscopy (NIRS) study. Schizophr Res 77: 65-73.
39. Larsen TK, McGlashan TH, Moe LC,. 1996. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 22: 241-256. (Pubitemid 26174572)
40. Lazeron RH, Rombouts SA, Machielsen WC, et al,. 2000. Visualizing brain activation during planning: the tower of London test adapted for functional MR imaging. AJNR Am J Neuroradiol 21: 1407-1414.
41. Liddle PF, Morris DL,. 1991. Schizophrenic syndromes and frontal lobe performance. Br J Psychiatry 158: 340-345.
42. MacDonald AW, 3rd, Carter CS, Kerns JG, et al,. 2005. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. Am J Psychiatry 162: 475-484. (Pubitemid 40343914)
43. Mahurin RK, Velligan DI, Miller AL,. 1998. Executive-frontal lobe cognitive dysfunction in schizophrenia: a symptom subtype analysis. Psychiatry Res 79: 139-149. (Pubitemid 28308487)
44. Matsui M, Sumiyoshi T, Arai H, et al,. 2008. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 280-287.
45. McEvoy JP, Hogarty GE, Steingard S,. 1991. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48: 739-745.
46. McEvoy JP, Lieberman JA, Perkins DO, et al,. 2007. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1050-1060. (Pubitemid 47121394)
47. Meltzer HY, Thompson PA, Lee MA, et al,. 1996. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 14: 27S-33S. (Pubitemid 26096727)
48. Mesholam-Gately RI, Giuliano AJ, Goff KP, et al,. 2009. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23: 315-336.
49. Mishara AL, Goldberg TE,. 2004. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55: 1013-1022. (Pubitemid 38581917)
50. Miura S., 2008. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with risperidone. Jpn J Clin Psychopharmacol 11: 297-314.
51. Miyake N, Miyamoto S, Takeuchi A, et al,. 2008. Effect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: A randomized double-blind comparison with risperidone. Jpn J Clin Psychopharmacol 11: 1329-1336.
52. Miyamoto S, Fleischhacker WW, Lieberman JA,. in press. Pharmacologic treatment of schizophrenia. In Comprehensive Care of Schizophrenia, 2nd edn, Murray R, Lieberman JA, (eds). Oxford University Press: New York.
53. Miyamoto S, Merrill DB, Lieberman JA, et al,. 2008. Antipsychotic drugs. In Psychiatry, 3rd edn, Tasman A, Kay J, Lieberman JA, et al. (eds). John Wiley & Sons: Chichester; 2161-2201.
54. Morris RG, Ahmed S, Syed GM, et al,. 1993. Neural correlates of planning ability: frontal lobe activation during the Tower of London test. Neuropsychologia 31: 1367-1378. (Pubitemid 24016959)
55. Murasaki M,. 2007a. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol 10: 2059-2079.
56. Murasaki M,. 2007b. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Kanagawa Region Clinical Psychopharmacology Study Group). Jpn J Clin Psychopharmacol 10: 2241-2257.
57. Noda Y, Kurumiya S, Miura Y, et al,. 1993. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b] pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. J Pharmacol Exp Ther 265: 745-751. (Pubitemid 23315582)
58. Ogino S, Miyamoto S, Tenjin T, et al,. 2011. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35: 78-83.
59. Ohoyama K, Yamamura S, Hamaguchi T, et al,. 2011. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur J Pharmacol 653: 47-57.
60. Oka M, Noda Y, Ochi Y, et al,. 1993. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 264: 158-165. (Pubitemid 23309197)
61. Osada K, Miyamoto S, Maruta S, et al,. 2009. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to assess the safety and efficacy in patients with schizophrenia (continuation of two long-term studies by request from patients). Jpn J Clin Psychopharmacol 12: 2337-2351.
62. Owen AM, Doyon J, Petrides M, et al,. 1996. Planning and spatial working memory: a positron emission tomography study in humans. Eur J Neurosci 8: 353-364. (Pubitemid 26041333)
63. Perkins DO, Gu H, Weiden PJ, et al,. 2008. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 69: 106-113. (Pubitemid 351282003)
64. Robinson D,. 2010. First-episode schizophrenia. CNS Spectr 15: 4-7.
65. Salimi K, Jarskog LF, Lieberman JA,. 2009. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs 23: 837-855.
66. Saykin AJ, Shtasel DL, Gur RE, et al,. 1994. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51: 124-131.
67. Snitz BE, MacDonald A, 3rd, Cohen JD, et al,. 2005. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry 162: 2322-2329. (Pubitemid 41740211)
68. Sumiyoshi T, Bubenikova-Valesova V, Horacek J, et al,. 2008. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther 25: 1037-1056.
69. Tomida K, Takahashi N, Saito S, et al,. 2010. Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin Neurosci 64: 62-69.
70. van Veelen NM, Vink M, Ramsey NF, et al,. 2010. Left dorsolateral prefrontal cortex dysfunction in medication-naive schizophrenia. Schizophr Res 123: 22-29.
71. Velligan DI, Kern RS, Gold JM,. 2006. Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr Bull 32: 474-485. (Pubitemid 43992321)
72. Wilkinson G, Hesdon B, Wild D, et al,. 2000. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 177: 42-46. (Pubitemid 30450663)
73. Wolwer W, Brinkmeyer J, Riesbeck M, et al,. 2008. Neuropsychological impairments predict the clinical course in schizophrenia. Eur Arch Psychiatry Clin Neurosci 258 (Suppl 5): 28-34.
74. Woon PS, Chia MY, Chan WY, et al,. 2010. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34: 463-468.
75. Yang J, Bahk WM, Cho HS, et al,. 2010. Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol 33: 169-175.